1. In Vivo
  2. >>Business Strategy

Pfizer's Analyst Day: And Now, For Its Next Trick

Pfizer was vague in describing to analysts just how it would reduce costs by $4 billion per year by 2008. The FDA's announcement that it had asked Pfizer to remove the Cox-2 inhibitor Bextra from the market just days later complicates matters for the pharmaceutical giant. In any case, those hoping for a significant headcount reduction among Pfizer sales reps were surely disappointed.

At its much-anticipated analysts' meeting in early April, Pfizer Inc. was vague in explaining exactly how exactly the pharmaceutical giant would both trim an unexpectedly bulky $4 billion from its costs by 2008 (twice the figure expected by most analysts) and return the company to double-digit adjusted earnings growth as early as 2006 (2005, CFO David Shedlarz predicted, would see a modest profit decline). Quite a few observers suggest this can't be done without significant layoffs from sales force and R&D cuts that Pfizer says it won't resort to.

Now the company must pull off this Houdiniesque escape wearing the equivalent of a blindfold handed to it by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.